A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Srikala S. Sridhar, Christina M. Canil, Kim N. Chi, Sebastien J. Hotte, Scott Ernst, Lisa Wang, Eric X. Chen, Agnes Juhasz, Yun Yen, Peter Murray, James A. Zwiebel, Malcolm J. MooreТом:
67
Мова:
english
Сторінки:
7
DOI:
10.1007/s00280-010-1389-7
Date:
April, 2011
Файл:
PDF, 298 KB
english, 2011